Bexobrutideg
Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase).
Overview
Bexobrutideg (NX-5948) is a protein degrader developed by Nurix Therapeutics. Its target is BTK (Bruton tyrosine kinase) (the sponsor names BTK (Bruton's tyrosine kinase)). The sponsor states: NX-5948 is an oral, CNS-penetrant BTK degrader that removes the BTK protein rather than only inhibiting its activity, which the sponsor states may help overcome kinase-domain and scaffolding-mediated resistance mutations. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07516093 (Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL), in chronic lymphocytic leukaemia. The largest, NCT07516093, plans to enrol 620 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Bexobrutideg" OR ABSTRACT:"Bexobrutideg" OR TITLE:"NX-5948" OR ABSTRACT:"NX-5948") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bexobrutideg, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentDZD8586
Shares Chronic lymphocytic leukaemia and the tags pipeline, ctgov-ingest.
- TreatmentCTX112
Shares Chronic lymphocytic leukaemia and the tags pipeline, ctgov-ingest.
- TreatmentICP-248
Shares Chronic lymphocytic leukaemia and the tags pipeline, ctgov-ingest.
- TreatmentKRT-232
Shares Chronic lymphocytic leukaemia and the tags pipeline, ctgov-ingest.
- TreatmentRocbrutinib
Shares Chronic lymphocytic leukaemia and the tags pipeline, ctgov-ingest.
- TreatmentA166
Shares the tags pipeline, ctgov-ingest.
- TreatmentAAA817
Shares the tags pipeline, ctgov-ingest.
- TreatmentABBV-706
Shares the tags pipeline, ctgov-ingest.